Alan K Burnett

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8011301/publications.pdf

Version: 2024-02-01

147 papers	9,499 citations	100601 38 h-index	43601 95 g-index
150 all docs	150 docs citations	150 times ranked	7887 citing authors

#	Article	IF	Citations
1	Therapy for isocitrate dehydrogenase 2 (IDH2)^{R172}â€mutant acute myeloid leukaemia. British Journal of Haematology, 2022, 196, 1348-1352.	1.2	3
2	Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study*. British Journal of Haematology, 2021, 192, 832-842.	1.2	15
3	Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses. Journal of Clinical Oncology, 2021, 39, 890-901.	0.8	20
4	Additional impact of mutational genotype on prognostic determination in resistant and relapsed acute myeloid leukaemia. Leukemia Research, 2021, 108, 106553.	0.4	0
5	Genome-wide association study identifies susceptibility loci for acute myeloid leukemia. Nature Communications, 2021, 12, 6233.	5.8	17
6	Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative study. Haematologica, 2020, 105, 161-169.	1.7	15
7	Analysis of the clinical impact of NPM1 mutant allele burden in a large cohort of younger adult patients with acute myeloid leukaemia. British Journal of Haematology, 2020, 188, 852-859.	1.2	13
8	AML: New Drugs but New Challenges. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 341-350.	0.2	23
9	The clinical impact of mutant DNMT3A R882 variant allele frequency in acute myeloid leukaemia. British Journal of Haematology, 2020, 189, e81-e86.	1.2	5
10	Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia. Blood Advances, 2019, 3, 3052-3061.	2.5	15
11	No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC/NCRI trials. Blood, 2018, 131, 468-471.	0.6	36
12	CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML. Blood Advances, 2018, 2, 964-968.	2.5	15
13	Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncology, The, 2018, 19, 889-903.	5.1	205
14	Addition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: experience from the UK NCRI AML17 trial. Haematologica, 2018, 103, 1654-1661.	1.7	14
15	Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: long-term follow-up of the AML17 trial. Blood, 2018, 132, 1452-1454.	0.6	42
16	Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations. Journal of Clinical Oncology, 2018, 36, 1486-1497.	0.8	151
17	A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML. Blood, 2017, 129, 1143-1154.	0.6	125
18	Relationship between event-free survival and overall survival in acute myeloid leukemia: a report from SWOG, HOVON/SAKK, and MRC/NCRI. Haematologica, 2016, 101, e284-e286.	1.7	18

#	Article	IF	Citations
19	Higher daunorubicin exposure benefits FLT3 mutated acute myeloid leukemia. Blood, 2016, 128, 449-452.	0.6	49
20	The value of molecular stratification for CEBPA^{DM} and NPM1^{MUT}FLT3^{WT} genotypes in older patients with acute myeloid leukaemia. British Journal of Haematology, 2016, 172, 573-580.	1.2	18
21	Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m2 with 6 mg/m2 in the NCRI AML17 Trial. Haematologica, 2016, 101, 724-731.	1.7	60
22	Normal Hematopoietic Progenitor Subsets Have Distinct Reactive Oxygen Species, BCL2 and Cell-Cycle Profiles That Are Decoupled from Maturation in Acute Myeloid Leukemia. PLoS ONE, 2016, 11, e0163291.	1.1	11
23	The targeted histone deacetylase inhibitor tefinostat (CHR-2845) shows selective in vitro efficacy in monocytoid-lineage leukaemias. Oncotarget, 2016, 7, 16650-16662.	0.8	12
24	Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia. Blood, 2015, 125, 2923-2932.	0.6	46
25	An immunophenotypic preâ€treatment predictor for poor response to induction chemotherapy in older acute myeloid leukaemia patients: blood frequency of CD34⁺ÂCD38^{low} blasts. British Journal of Haematology, 2015, 170, 80-84.	1.2	12
26	Cord Blood-Derived Quiescent CD34⁺ Cells Are More Transcriptionally Matched to AML Blasts Than Cytokine-Induced Normal Human Hematopoietic CD34⁺ Cells. Gene Expression, 2015, 16, 169-175.	0.5	0
27	A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood, 2015, 125, 3878-3885.	0.6	230
28	Simpson's Paradox and the Impact of Different DNMT3A Mutations on Outcome in Younger Adults With Acute Myeloid Leukemia. Journal of Clinical Oncology, 2015, 33, 2072-2083.	0.8	82
29	Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia. Blood, 2015, 125, 2985-2994.	0.6	42
30	Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncology, The, 2014, 15, 986-996.	5.1	549
31	Impact of FLT3ITD mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia. Blood, 2014, 124, 273-276.	0.6	108
32	A Comparison of Single Dose Gemtuzumab Ozogamicin 3mg/m2 and 6mg/m2 Combined with Induction Chemotherapy in Younger Patients with AML: Data from the UK NCRI AML17 Trial. Blood, 2014, 124, 2308-2308.	0.6	2
33	Molecular Detection of Minimal Residual Disease Provides the Most Powerful Independent Prognostic Factor Irrespective of Clonal Architecture in Nucleophosmin (NPM1) Mutant Acute Myeloid Leukemia. Blood, 2014, 124, 70-70.	0.6	8
34	A Randomised Assessment of Vosaroxin Monotherapy and Vosaroxin Combined with Low Dose Ara-C Versus Low Dose Ara-C in Older Patients with Acute Myeloid Leukaemia. Blood, 2014, 124, 3747-3747.	0.6	0
35	Optimization of Chemotherapy for Younger Patients With Acute Myeloid Leukemia: Results of the Medical Research Council AML15 Trial. Journal of Clinical Oncology, 2013, 31, 3360-3368.	0.8	333
36	Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival. Blood, 2013, 122, 1384-1394.	0.6	123

#	Article	IF	Citations
37	THE CHALLENGE OF AML IN OLDER PATIENTS. Mediterranean Journal of Hematology and Infectious Diseases, 2013, 5, e2013038.	0.5	8
38	Curability of Patients With Acute Myeloid Leukemia Who Did Not Undergo Transplantation in First Remission. Journal of Clinical Oncology, 2013, 31, 1293-1301.	0.8	183
39	The Targeted Histone Deacetylase Inhibitor Tefinostat (CHR-2845) Shows Selective In Vitro Efficacy In Monocytoid-Lineage Acute Myeloid Leukaemia (AML). Blood, 2013, 122, 1297-1297.	0.6	1
40	The Addition Of Gemtuzumab Ozogamicin (GO) To Induction Chemotherapy Reduces Relapse and Improves Survival In Patients Without Adverse Risk Karyotype: Results Of An Individual Patient Meta-Analysis Of The Five Randomised Trials. Blood, 2013, 122, 356-356.	0.6	11
41	Reasons For Survival Improvement In Core Binding Factor AML: A 25 Year Analysis Of The UK MRC/NCRI AML Trials. Blood, 2013, 122, 358-358.	0.6	9
42	The ATRA Question In AML: Lack Of Benefit Overall Or In Any Molecular Subgroup In The NCRI AML16 Trial. Blood, 2013, 122, 493-493.	0.6	3
43	AC220 (Quizartinib) Can Be Safely Combined With Conventional Chemotherapy In Older Patients With Newly Diagnosed Acute Myeloid Leukaemia: Experience From The AML18 Pilot Trial. Blood, 2013, 122, 622-622.	0.6	24
44	Effect of quizartinib (AC220) on response rates and long-term survival in elderly patients with FLT3-ITD positive or negative relapsed/refractory acute myeloid leukemia.. Journal of Clinical Oncology, 2013, 31, 7021-7021.	0.8	6
45	Prediction Of Therapeutic Resistance In Adult Acute Myeloid Leukemia: Analysis Of 4,550 Newly Diagnosed Patients From MRC/NCRI, HOVON/SAKK, SWOG, and MD Anderson Cancer Center. Blood, 2013, 122, 64-64.	0.6	2
46	New induction and postinduction strategies in acute myeloid leukemia. Current Opinion in Hematology, 2012, 19, 76-81.	1.2	11
47	Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy Improves Survival in Older Patients With Acute Myeloid Leukemia. Journal of Clinical Oncology, 2012, 30, 3924-3931.	0.8	370
48	Treatment of acute myeloid leukemia: are we making progress?. Hematology American Society of Hematology Education Program, 2012, 2012, 1-6.	0.9	66
49	The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with <scp>AML</scp>. British Journal of Haematology, 2012, 158, 519-522.	1.2	52
50	Treatment of acute myeloid leukemia: are we making progress?. Hematology American Society of Hematology Education Program, 2012, 2012, 1-6.	0.9	40
51	A Randomised Comparison of Clofarabine Versus Low Dose Ara-C As First Line Treatment for Older Patients with AML. Blood, 2012, 120, 889-889.	0.6	4
52	A Comparison of Daunorubicin/Ara-C (DA) Versus Daunorubicin/Clofarabine (DClo) and Two Versus Three Courses of Total Treatment for Older Patients with AML and High Risk MDS: Results of the UK NCRI AML16 Trial. Blood, 2012, 120, 892-892.	0.6	5
53	Prognostic Significance of the French-American-British (FAB) Morphologic Subclassification of â€œAcute Myeloid Leukemia, Not Otherwise Specifiedâ€•in the 2008 WHO Classification: Analysis of 5,848 Newly Diagnosed Patients From HOVON, MRC/NCRI, SWOG, and MD Anderson Cancer Center. Blood, 2012, 120, 540-540.	0.6	0
54	Activity of a Heptad of Transcription Factors Is Associated with Stem Cell Programs and Clinical Outcome in Acute Myeloid Leukaemia. Blood, 2012, 120, 3525-3525.	0.6	0

#	Article	IF	Citations
55	Therapeutic Advances in Acute Myeloid Leukemia. Journal of Clinical Oncology, 2011, 29, 487-494.	0.8	683
56	The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. Blood, 2011, 118, 409-412.	0.6	233
57	Who Should Be Transplanted in First Remission of Acute Myeloid Leukaemia?. Current Treatment Options in Oncology, 2011, 12, 329-340.	1.3	3
58	Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial. Journal of Clinical Oncology, 2011, 29, 369-377.	0.8	581
59	A Phase II Open-Label, Ac220 Monotherapy Efficacy Study In Patients with Refractory/Relapsed Flt3-Itd Positive Acute Myeloid Leukemia: Updated Interim Results. Blood, 2011, 118, 2576-2576.	0.6	12
60	Inhibition of BET Recruitment to Chromatin As An Effective Treatment for MLL-Fusion Leukaemia. Blood, 2011, 118, 55-55.	0.6	5
61	The Addition of Gemtuzumab Ozogamicin to Intensive Chemotherapy in Older Patients with AML Produces a Significant Improvement in Overall Survival: Results of the UK NCRI AML16 Randomized Trial. Blood, 2011, 118, 582-582.	0.6	12
62	Quantitation of Leukemic Stem Cell Populations Predicts Clinical Outcome in Acute Myeloid Leukaemia. Blood, 2011, 118, 638-638.	0.6	5
63	Single Nucleotide Polymorphism Array (SNP-A) Karyotype Is the Best Predictor of Prognosis In Normal Cytogenetics Acute Myeloid Leukaemia (AML). Blood, 2011, 118, 411-411.	0.6	0
64	Mutations in a Large Cohort of Young Adult Patients with Core Binding Factor Acute Myeloid Leukemia: Impact on Outcome and the Selection of Patients for Alternative Treatment Including Transplantation in First Complete Remission. Blood, 2011, 118, 419-419.	0.6	0
65	Histone H3 Methylation Mediates All-Trans-Retinoic Acid Responsiveness in Acute Myeloid Leukemia. Blood, 2011, 118, 224-224.	0.6	0
66	The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA. Blood, 2010, 115, 948-956.	0.6	105
67	European Development of Clofarabine as Treatment for Older Patients With Acute Myeloid Leukemia Considered Unsuitable for Intensive Chemotherapy. Journal of Clinical Oncology, 2010, 28, 2389-2395.	0.8	148
68	Attempts to Optimize Induction and Consolidation Treatment in Acute Myeloid Leukemia: Results of the MRC AML12 Trial. Journal of Clinical Oncology, 2010, 28, 586-595.	0.8	199
69	Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood, 2010, 116, 354-365.	0.6	1,661
70	Younger Adult Acute Myeloid Leukemia (AML) Patients with IDH2-R140 Mutations Have a Significantly Better Prognosis Than Those with Either IDH2-R172 or IDH1 Mutations. Blood, 2010, 116, 100-100.	0.6	1
71	The Addition of Gemtuzumab Ozogamicin to Low Dose Ara-C Improves Remission Rates but Not Survival: Results of the UK LRF AML14 and NCRI AML16 â€œPick a Winnerâ€•Comparison. Blood, 2010, 116, 18-18.	0.6	11
72	A Phase Ib Study Combining the mTOR Inhibitor Everolimus (RAD001) with Low-Dose Cytarabine In Untreated Elderly AML. Blood, 2010, 116, 3299-3299.	0.6	6

#	Article	IF	Citations
73	Prognostic Significance of Cryptic Genomic Aberrations In AML with Normal Karyotype. Blood, 2010, 116, 2729-2729.	0.6	0
74	Detection of Immunophenotypic Residual Disease After Induction Therapy Is An Independent Prognostic Factor for Duration of Remission In Older AML Patients Treated Intensively. Blood, 2010, 116, 2714-2714.	0.6	0
75	A Distinct Signature of Natural Killer Cell KIR Gene Frequencies In Secondary AML Compared with De Novo AML and Normal Controls. Blood, 2010, 116, 1697-1697.	0.6	0
76	Co-Existence of LMPP-Like and GMP-Like Leukemia Stem Cells In Acute Myeloid Leukemia. Blood, 2010, 116, 91-91.	0.6	0
77	Analysis of the Interaction of Induction Regimens with P-Glycoprotein Expression In Patients with Acute Myeloid Leukaemia: Results From the MRC AML15 Trial. Blood, 2010, 116, 2724-2724.	0.6	5
78	The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial. British Journal of Haematology, 2009, 145, 318-332.	1.2	134
79	2â€²â€“Cyanoâ€“2â€²â€“Deoxyarabinofuranosylcytosine Is Active in Acute Myeloid Leukaemia and Acts in Synergy with Cytarabine.. Blood, 2009, 114, 4153-4153.	0.6	1
80	Topoisomerase II Inhibitor Voreloxin Causes Cell Cycle Arrest and Apoptosis in Acute Myeloid Leukaemia Cells and Acts in Synergy with Cytarabine.. Blood, 2009, 114, 4152-4152.	0.6	0
81	The Cyclin Dependent Kinase 2, 7 and 9 Inhibitor SNS-032 Has Single Agent Activity in Acute Myeloid Leukaemia Cells and Is Highly Synergistic with Cytarabine.. Blood, 2009, 114, 1059-1059.	0.6	0
82	A Retrospective Comparison of Matched Elderly Patients Treated with Laromustine (CloretazineÂ®) or Best Supportive Care or Low Dose Ara-C in the LRF AML14 Trial. Blood, 2008, 112, 2960-2960.	0.6	1
83	Low Dose Ara-C Versus Low Dose Ara-C and Tipifarnib: Result of the UK NCRI AML16 â€œPick a Winnerâ€• Comparison. Blood, 2008, 112, 2962-2962.	0.6	4
84	Standard Consolidation/Maintenance Chemotherapy Is Consistently Superior to a Single Autologous Transplant for Adult Patients with Acute Lymphoblastic Leukemia: Results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood, 2008, 112, 3314-3314.	0.6	1
85	The Impact of FLT3-ITD and NPM1 Mutational Status on the Outcome of ATRA Therapy in Patients with Non-APL AML: Results of the UK MRC AML12 Trial. Blood, 2008, 112, 554-554.	0.6	4
86	Predictive Value of Minimal Residual Disease (MRD) Monitoring by RQ-PCR in WT1 Positive Patients Entered in the UK MRC AML-15 Trial. Blood, 2008, 112, 697-697.	0.6	2
87	Ras Promotes Production of Reactive Oxygen Species in Normal Human CD34+ Cells: Role in Promoting Cell Survival and Protein Phosphorylation. Blood, 2008, 112, 3797-3797.	0.6	0
88	The Sequence-Selective DNA Cross-Linking Agent SJG-136 (SG2000, BN2629) Is Highly Potent in Multiple Myeloma Cells and Is Synergistic with Bortezimib. Blood, 2008, 112, 5166-5166.	0.6	0
89	The DNA Crosslinking Agent SJG-136 (SG2000, BN2629) Is Highly Potent in Acute Myeloid Leukaemia and Is Synergistic with Cytarabine. Blood, 2008, 112, 4013-4013.	0.6	0
90	The Impact of MN1 Over-Expression on the Outcome of Younger Patients with AML Treated with Intensive Chemotherapy with or without ATRA Therapy. Blood, 2008, 112, 2978-2978.	0.6	1

#	Article	IF	Citations
91	Pharmacological Inhibition of NF-KB Underpins the Strong Synergy Between LC-1 and Fludarabine in Chronic Lymphocytic Leukaemia Cells. Blood, 2008, 112, 380-380.	0.6	0
92	Rel a Is a Novel Prognostic Marker in CLL That Is Independent of VH Gene Mutation Status, CD38 Expression and ZAP-70 Expression. Blood, 2008, 112, 4153-4153.	0.6	0
93	The Parthenolide Derivative LC-1 Is An Effective Single Agent and Is Highly Synergistic with Existing Therapies in Multiple Myeloma.. Blood, 2008, 112, 1708-1708.	0.6	0
94	Azacytidine as a Maintenance Therapy in Elderly AML Progressively Demethylates CpG Sites within the p16 Gene. Blood, 2008, 112, 4466-4466.	0.6	2
95	CSL-TREX: A Novel Alternatively Spliced Isoform of CSL (RBPJ-K) Predominates Over the Full-Length Isoform in Many Patients with Acute Myeloid Leukaemia, Can Activate Notch Signalling and Is Associated with Improved Outcome.. Blood, 2008, 112, 3364-3364.	0.6	1
96	MRC trials in acute myeloblastic luekemia: Where have we got to?. Leukemia and Lymphoma, 2007, 48, 2289-2290.	0.6	4
97	Targeting Treatment in AML. Hematology American Society of Hematology Education Program, 2007, 2007, 429-434.	0.9	9
98	A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer, 2007, 109, 1114-1124.	2.0	559
99	A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. , 2007, 109, 1114.		1
100	Idarubicin and ATRA Is as Effective as MRC Chemotherapy in Patients with Acute Promyelocytic Leukaemia with Lower Toxicity and Resource Usage: Preliminary Results of the MRC AML15 Trial.. Blood, 2007, 110, 589-589.	0.6	17
101	Tipifarnib in acute myeloid leukemia. Drugs of Today, 2007, 43, 795.	0.7	6
102	Mutation of the Wilmsâ€™ Tumor 1 Gene Is a Poor Prognostic Factor Associated with Chemoresistance in Normal Karyotype Acute Myeloid Leukemia.. Blood, 2007, 110, 361-361.	0.6	0
103	Minimal Residual Disease Monitoring by RQ-PCR in Core Binding Factor Positive AML Allows Risk-Stratification and Predicts Relapse: Results of the UK MRC AML-15 Trial.. Blood, 2007, 110, 543-543.	0.6	0
104	L-Gossypol Has Significant In Vitro Activity Against Primary Acute Myeloid Leukaemia Cells, Inducing Apoptosis through the Intrinsic Pathway.. Blood, 2007, 110, 4180-4180.	0.6	0
105	The Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy for AML Improves Disease Free Survival without Extra Toxicity: Preliminary Analysis of 1115 Patients in the MRC AML15 Trial.. Blood, 2006, 108, 13-13.	0.6	54
106	A Sensitive Risk Score for Directing Treatment in Younger Patients with AML.. Blood, 2006, 108, 18-18.	0.6	12
107	The Feasibility of Combining Daunorubicin, Clofarabine and Gemtuzumab Ozogamicin Is Feasible and Effective. A Pilot Study.. Blood, 2006, 108, 1950-1950.	0.6	4
108	Effectiveness of Clofarabine in Elderly AML Patients with Adverse Cytogenetics Unfit for Intensive Chemotherapy.. Blood, 2006, 108, 1985-1985.	0.6	2

#	Article	IF	Citations
109	A Phase II Study (Biov-121) of Clofarabine Monotherapy First Line in Patients Aged 65 Years or Older with Acute Myeloid Leukemia for Whom Standard Intensive Chemotherapy Is Not Considered Suitable.. Blood, 2006, 108, 425-425.	0.6	20
110	Aberrant Megakaryocyte Antigen Expression on Myelodysplastic Erythroid Cells: Role of Protein Kinase C?.. Blood, 2006, 108, 2625-2625.	0.6	0
111	Competing Influences of Genetic and Leukaemia-Specific Factors on P-Glycoprotein Expression in Blasts from 817 Patients Entered into the NCRN AML14 and 15 Trials.. Blood, 2006, 108, 835-835.	0.6	1
112	Inhibition of Cellular Aminopeptidases as Novel Therapy for AML.. Blood, 2006, 108, 2588-2588.	0.6	0
113	NF Kappa B as a Therapeutic Target in AML.. Blood, 2006, 108, 2587-2587.	0.6	5
114	Long-term results of the MRC AML10 trial. Clinical Advances in Hematology and Oncology, 2006, 4, 445-51.	0.3	16
115	The treatment of AML: Current status and novel approaches. Hematology, 2005, 10, 50-53.	0.7	17
116	The Aurora Kinase Inhibitor AZD1152 Causes Perturbation of Cell Cycle Distribution in Cell Lines and Primary AML Samples.. Blood, 2005, 106, 2759-2759.	0.6	2
117	Modification or Dose or Treatment Duration Has No Impact on Outcome of AML in Older Patients: Preliminary Results of the UK NCRI AML14 Trial.. Blood, 2005, 106, 543-543.	0.6	6
118	The Novel Anti-Leukemic Agent LC-1, Is Preferentially Cytotoxic in CLL Cells Derived from Poor Prognostic Subsets.. Blood, 2005, 106, 2981-2981.	0.6	0
119	A European network for AML. The Hematology Journal, 2004, 5, S44-S45.	2.0	0
120	Does All-Transretinoic Acid (ATRA) Have a Role in Non-APL Acute Myeloid Leukaemia?: Results from 1666 Patients in Three MRC Trials.. Blood, 2004, 104, 1794-1794.	0.6	5
121	The Impact of Transplant in AML in 2nd CR: A Prospective Study of 741 in the MRC AML 10 and 12 Trials.. Blood, 2004, 104, 620-620.	0.6	8
122	Daunorubicin and Cytarabine Compared with Daunorubicin, Cytarabine and the MDR1 Reversal Agent PSC-833 in Elderly Patients with Acute Myelogenous Leukemia.. Blood, 2004, 104, 863-863.	0.6	1
123	A Phase 2 Evaluation of Single Agent Clofarabine as First Line Treatment for Older Patients with AML Who Are Not Considered Fit for Intensive Chemotherapy.. Blood, 2004, 104, 869-869.	0.6	13
124	Low Dose Ara-C Versus Hydroxyurea with or without Retinoid in Older Patients Not Considered Fit for Intensive Chemotherapy: The UK NCRI AML14 Trial.. Blood, 2004, 104, 872-872.	0.6	17
125	CEP701 and PKC412 Predictably and Reliably Inhibit FLT3 Phosphorylation in Primary AML Blasts but Their Induction of a Cytotoxic Response Appears to Be Much More Variable.. Blood, 2004, 104, 95-95.	0.6	2
126	P-Glycoprotein Overexpresion and Internal Tandem Duplications of FLT3 Are Characteristic of Discrete Populations of Elderly AML Patients.. Blood, 2004, 104, 196-196.	0.6	2

#	Article	IF	Citations
127	Hsp90 Expression in Acute Myeloid Leukaemia.. Blood, 2004, 104, 4471-4471.	0.6	0
128	Heat Shock Protein 90 (Hsp90) Inhibition Results in Apoptotic Killing of Primary AML Cells with FLT3/ITD Mutation.. Blood, 2004, 104, 2525-2525.	0.6	0
129	ACUTE MYELOID LEUKEMIA: TREATMENTOF ADULTS UNDER 60 YEARS. Reviews in Clinical and Experimental Hematology, 2002, 6, 26-45.	0.1	38
130	Current Controversies: Which Patients With Acute Myeloid Leukaemia Should Receive A Bone Marrow Transplantation? - An Adult Treater's View. British Journal of Haematology, 2002, 118, 357-364.	1.2	51
131	The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. British Journal of Haematology, 2002, 118, 385-400.	1.2	295
132	Gemtuzumab ozogamicin. Drugs, 2001, 61, 1323-1324.	4.9	0
133	Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood, 2001, 98, 1302-1311.	0.6	415
134	Evaluating the contribution of allogeneic and autologous transplantation to the management of acute myeloid leukemia in adults. Cancer Chemotherapy and Pharmacology, 2001, 48, S53-S58.	1.1	13
135	Comparison of â€˜sequentialâ€™ versus â€˜standardâ€™ chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial. British Journal of Haematology, 2001, 113, 713-726.	1.2	92
136	AnIn VivoandIn VitroComparison of the Effects of b2-a2 and b3-a2 p210BCR-ABLSplice Variants on Murine 32D Cells. Leukemia and Lymphoma, 2000, 37, 393-404.	0.6	7
137	The C282Y Mutation of HFE Is Another Male-Specific Risk Factor for Childhood Acute Lymphoblastic Leukemia. Blood, 1999, 94, 3957-3958.	0.6	45
138	Unravelling an HLA-DR Association in Childhood Acute Lymphoblastic Leukemia. Blood, 1999, 94, 694-700.	0.6	92
139	A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. British Journal of Haematology, 1999, 107, 69-79.	1.2	376
140	Identification of the t(15;17) in AML FAB types other than M3: evaluation of the role of molecular screening for the PML/RARalpha rearrangement in newly diagnosed AML. British Journal of Haematology, 1999, 105, 198-207.	1.2	43
141	Severe adverse impact on sexual functioning and fertility of bone marrow transplantation, either allogeneic or autologous, compared with consolidation chemotherapy alone. , 1999, 86, 1231-1239.		110
142	Identification of the t(15;17) in AML FAB types other than M3: evaluation of the role of molecular screening for the PML/RARalpha rearrangement in newly diagnosed AML. British Journal of Haematology, 1999, 105, 198-207.	1.2	14
143	Unravelling an HLA-DR Association in Childhood Acute Lymphoblastic Leukemia. Blood, 1999, 94, 694-700.	0.6	21
144	Molecular evidence for a common leukaemic progenitor in acute mixed lymphoid and myeloid leukaemia. British Journal of Haematology, 1996, 92, 131-133.	1.2	7

#	Article	IF	Citations
145	Human Major Histocompatibility Complex Contains Several Leukemia Susceptibility Genes. Leukemia and Lymphoma, 1994, 12, 211-222.	0.6	43
146	Thymusâ€leukaemia antigens: The haemochromatosis gene product?. Immunology and Cell Biology, 1994, 72, 435-439.	1.0	7
147	Management of acute myeloid leukemia. , 0, , 26-42.		0